Kiniksa Pharmaceuticals International, plc Deferred Foreign Income Tax Expense (Benefit)
Kiniksa Pharmaceuticals International, plc (KNSA) reported Deferred Foreign Income Tax Expense (Benefit) of $15.92 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-24
- Kiniksa Pharmaceuticals International, plc deferred foreign income tax expense (benefit) for fiscal 2025 was $15.92M, a 33.33% increase from fiscal 2024.
- Kiniksa Pharmaceuticals International, plc deferred foreign income tax expense (benefit) for fiscal 2024 was $11.94M.
- Kiniksa Pharmaceuticals International, plc deferred foreign income tax expense (benefit) for fiscal 2023 was -$15.71M.
- Kiniksa Pharmaceuticals International, plc deferred foreign income tax expense (benefit) for fiscal 2022 was -$185.50M, a 1686418.18% decline from fiscal 2021.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $15.92M 10-K · filed 2026-02-24 |
| 2024-12-31 | $11.94M 10-K · filed 2026-02-24 |
| 2023-12-31 | -$15.71M 10-K · filed 2026-02-24 |
| 2022-12-31 | -$185.50M 10-K · filed 2025-02-25 |
| 2021-12-31 | $11.00K 10-K · filed 2024-02-28 |
| 2020-12-31 | -$10.00K 10-K · filed 2023-03-02 |